ArticleJAAD international2026
Originator versus biosimilar adalimumab in hidradenitis suppurativa: A multicenter real-world analysis of clinical response, maintenance of response, and switching.
Article in JAAD international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adalimumab is a mainstay treatment for hidradenitis suppurativa (HS); however, high-costs limit accessibility. While biosimilars offer an affordable alternative, concerns remain regarding clinical equivalence and the impact of switching. Objective: To evaluate the clinical response of originator versus biosimilar adalimumab in HS and assess outcomes following nonmedical switching. Methods: This multicenter, real-world study included treatment naïve HS patients initiated on originator or biosimilar adalimumab between April 2021 and December 2024. Outcomes were compared between patients remaining on originator and those switched to biosimilar after 16 weeks. Clinical responses were assessed using Hidradenitis Suppurativa Clinical Response 50, Hidradenitis Suppurativa Clinical Response 75, and International Hidradenitis Suppurativa Severity Scoring System 55, with time-to-event analyses evaluating loss of clinical response. Results: Patients on originator adalimumab ( Limitations: Limitations include its retrospective design and variable biosimilar formulations. Conclusion: Significant differences in clinical response, loss of response, and time-to-event analysis between originator and biosimilar adalimumab in HS underscore the need for consistent treatment and robust monitoring to optimize management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.